Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647752 | 0.92 | USP2 (0.44) | CYP11B2PIK3R1PIK3CAUSP2SMN1; SMN2 | |
| SCHEMBL24582054 | 0.90 | USP2 (0.41) | PIK3R1PIK3CAUSP2SMN1; SMN2DDB1 | |
| SCHEMBL22999897 | 0.86 | USP2 (0.42) | PIK3R1PIK3CAUSP2SMN1; SMN2DDB1 | |
| SCHEMBL31566777 | 0.85 | USP2 (0.42) | CYP11B2PIK3R1PIK3CAUSP30PIK3CD | |
| SCHEMBL3411664 | 0.85 | PIK3R1 (0.40) | CYP11B2PIK3R1PIK3CAUSP30PIK3CD | |
| SCHEMBL16502101 | 0.84 | USP2 (0.43) | PIK3R1PIK3CAPIK3CDPIK3CBUSP2 | |
| SCHEMBL21513415 | 0.84 | HPGD (0.46) | CYP11B2PIK3R1PIK3CAUSP30PIK3CD | |
| SCHEMBL650224 | 0.82 | L3MBTL1 (0.41) | PIK3R1PIK3CASMN1; SMN2 | |
| SCHEMBL16835469 | 0.81 | CYP11B2 (0.51) | CYP11B2USP30HDAC2USP2SMN1; SMN2 | |
| SCHEMBL31566523 | 0.81 | USP2 (0.39) | CYP11B2PIK3R1PIK3CAUSP30PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136174-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-30 | — | — | WO | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2262795-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2257543-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | AstraZeneca AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009110844-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | CHRM1, CHRM2, CHRM3 | CYP11B2 611/4885PIK3R1 2361/4885PIK3CA 2310/4885 |
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | CYP11B2 994/4885PIK3R1 4410/4885PIK3CA 3440/4885 |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | CYP11B2 928/4885PIK3R1 2185/4885PIK3CA 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.